Drugs / Hemospan
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00494949 | Apr 2003 → Jul 2006 | hypotensive disorder | Sangart | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00633659 | Sep 2007 → Jun 2008 | limb ischemia | Sangart | Completed | No outcome recorded |
| Phase 2 | NCT00425334 | Jul 2005 → Oct 2007 | prostate cancer | Sangart | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00421200 | Feb 2007 → May 2008 | hypotensive disorder, ischemic disease | Sangart | Completed | No outcome recorded |
| Phase 3 | NCT00420277 | Feb 2007 → Mar 2008 | hypotensive disorder, ischemic disease | Sangart | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemospan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00420277 ↗ |
| Known as | MP4OX | “Hemospan (MP4OX)” NCT00421200 ↗ |
| Modality | Protein / enzyme biologic | “Hemospan is a novel hemoglobin-based oxygen carrier” NCT00425334 ↗ |